Janssen Biotech, Inc.

Boehringer Ingelheim International Gmbh

Janssen Pharmaceutica Nv

Rajkumar Ganesan

Sanjaya Singh

Iqbal S Grewal

Jinquan Luo

Priyanka Gupta

Adam Zwolak

Fang Yi

Sherry La Porte

Sathyadevi Venkataramani

Michael Riis Hansen

Raymond Brittingham

John Lee

Justin M Scheer

Paul Adam

Pankaj Gupta

Michael Dziegelewski

Philip Nicholas Gorman

Vladimir H Voynov

Colleen Kane

Susanne Hipp

Theresa Marie McDevitt

Fei Shen

Triveni K Bhatt

Degang Song

Danlin Yang

Scott R Brodeur

Jun Chen

Leo Thomas

Steven Jacobs

Sheng-Jiun Wu

Marc Mercken

Ricardo Attar

Chichi Huang

Wilson Edwards

Manuel Sepulveda

Rachel Rebecca Barrett

Francois Gaudet

Otmar Schaaf

Ulrike Philippar

Yingzhe Li

Sylvie Laquerre

Philip L Cooper

Bianca Van Broeck

Fei Han

Juergen Prestle

Melanie Wurm

Markus Zettl

Michael Dennis Feldkamp

Dongmei Liu

Cassandra L Lowenstein

Helen Haixia Wu

Dirk Brehmer

Nina Zippel

Bradley J Heidrich

Yonghong Zhao

Martin Jack Borrok, Iii

Sathya Venkataramani

Jaclyn Hoover

Nele Vloemans

Anna Kuchnio

Ninkka Tamot

Naresh Kumar

Kyle J Bednar

Bruna De Andrade Pereira

Paul B Harvilla

Ian White

Rajitha Doddareddy

Jark Boettcher

Carmen Baca Jones

Irmgard Maria Rita Hofmann

Kristin Laura Bovat

Jennifer Ahlberg

Marcio Lasaro

Sven Mostboeck

Desiree De Lange

Szeman Chan

Natasa Obermajer

Simon Plyte

Julien Häsler

Shana Versmissen

Kelly Van De Ven

Theodore D Petley

Michael Russell

Robin Ernst

Chia-Hung Tsai

The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Proteins comprising CD3 antigen binding domains and uses thereof

Provided herein, in certain aspects, are antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.

Immune targeting molecules and uses thereof

Anti-Vβ17/anti-CD123 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies.

Anti-Vβ17/anti-CD123 bispecific antibodies

Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Antibody targeting CD22 and CD79B

The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Multi-specific binding proteins for cancer treatment

Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.

Materials and methods for multidirectional biotransportation in virotherapeutics

Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.

Materials and methods for enhanced linker targeting

Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.

Trispecific antibody targeting CD79b, CD20, and CD3

Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) Vγ9 (TRGV9), TCR Vδ2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.

Compositions and methods for modulating delta gamma chain mediated immunity

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

GPRC5D chimeric antigen receptors and cells expressing the same

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof

Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (iPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.

Materials and methods for the manufacture of pluripotent stem cells

Anti-Vβ17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

Methods and compositions for modulating beta chain mediated immunity

Growing community of inventors

Blue Bell, PA, United States of America

Rajkumar Ganesan